Common errors, pitfalls, and management of complications of prostate biopsy The most common diagnostic and procedural challenges of transrectal fusion prostate biopsy in the initial diagnosis of clinically significant prostate cancer

被引:0
|
作者
Enzinger, Benazir [1 ]
Pfitzinger, Paulo Leonardo [1 ]
Ebner, Benedikt [1 ]
Ivanova, Troya [1 ]
Volz, Yannic [1 ]
Apfelbeck, Maria [1 ]
Kazmierczak, Philipp [2 ]
Stief, Christian [1 ]
Chaloupka, Michael [1 ]
机构
[1] LMU Klinikum, Urol Klin & Poliklin, Marchioninistr 15, D-81377 Munich, Germany
[2] LMU Klinikum, Klinik & Poliklin Radiol, Marchioninistr 15, D-81377 Munich, Germany
来源
UROLOGIE | 2023年 / 62卷 / 05期
关键词
Prostate cancer; Risk stratification; Fusion biopsy; Transperineal approach; Infections; ULTRASOUND-GUIDED BIOPSY; INFECTIOUS COMPLICATIONS; RISK CALCULATOR; ACCURACY;
D O I
10.1007/s00120-023-02063-y
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Transrectal (TR) prostate biopsy is the gold standard in diagnosis of prostate cancer (PC). It requires a precise and safe technique for sample acquisition.Objective: Several approaches will be discussed to avoid overdiagnosis, false-negative results, and complications of the procedure.Materials and methods: We analyzed national and European guidelines, systematic reviews, meta-analyses, as well as prospective and retrospective studies to describe current trends in indication and performance of biopsies.Results: Incorporation of risk calculators and magnetic resonance imaging (MRI) into daily routine reduces biopsy rates and results in a more precise diagnosis of clinically significant prostate cancer (csPC). Combination of random- and MRI-fusion guided biopsy-but also extending the radius of sampling by 10 mm beyond the MRI lesion and a transperineal (TP) sampling approach - lead to a higher tumor-detection rate. Bleeding is the most common complication after prostate biopsy and is usually self-limiting. Postbiopsy infection rates can be reduced through TP biopsy.Conclusion: TR MRI-fusion guided biopsy is a widely acknowledged tool in primary diagnostics of csPC. Higher detection rates and safety can be achieved through a TP sampling approach.
引用
收藏
页码:479 / 486
页数:8
相关论文
共 50 条
  • [1] Häufige Fehler, „Pitfalls“ und Komplikationsmanagement der ProstatabiopsieDie häufigsten diagnostischen und prozeduralen Herausforderungen der transrektalen Fusionsbiopsie der Prostata bei Erstdiagnose eines klinisch signifikanten ProstatakarzinomsCommon errors, pitfalls, and management of complications of prostate biopsyThe most common diagnostic and procedural challenges of transrectal fusion prostate biopsy in the initial diagnosis of clinically significant prostate cancer
    Benazir Enzinger
    Paulo Leonardo Pfitzinger
    Benedikt Ebner
    Troya Ivanova
    Yannic Volz
    Maria Apfelbeck
    Philipp Kazmierczak
    Christian Stief
    Michael Chaloupka
    Die Urologie, 2023, 62 (5) : 479 - 486
  • [2] The role of MRI/TRUS fusion biopsy in the diagnosis of clinically significant prostate cancer
    Benelli, Andrea
    Vaccaro, Chiara
    Guzzo, Sonia
    Nedbal, Carlotta
    Varca, Virginia
    Gregori, Andrea
    THERAPEUTIC ADVANCES IN UROLOGY, 2020, 12
  • [3] Improving Detection of Clinically Significant Prostate Cancer: Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Guided Prostate Biopsy
    Rastinehad, Ardeshir R.
    Turkbey, Baris
    Salami, Simpa S.
    Yaskiv, Oksana
    George, Arvin K.
    Fakhoury, Mathew
    Beecher, Karin
    Vira, Manish A.
    Kavoussi, Louis R.
    Siegel, David N.
    Villani, Robert
    Ben-Levi, Eran
    JOURNAL OF UROLOGY, 2014, 191 (06) : 1749 - 1754
  • [4] Multiparametric MRI Fusion-Guided Prostate Biopsy for Detection of Clinically Significant Prostate Cancer Eliminates the Systemic Prostate Biopsy
    Matulevicius, Augustinas
    Bakavicius, Arnas
    Ulys, Albertas
    Trakymas, Mantas
    Usinskiene, Jurgita
    Naruseviciute, Ieva
    Sabaliauskaite, Rasa
    Zukauskaite, Kristina
    Jarmalaite, Sonata
    Jankevicius, Feliksas
    APPLIED SCIENCES-BASEL, 2022, 12 (19):
  • [5] Value of cognitive fusion targeted and standard systematic transrectal prostate biopsy for prostate cancer diagnosis
    Yu, Lu-Ping
    Du, Yi-Qing
    Sun, Yi-Ran
    Qin, Cai-Peng
    Yang, Wen-Bo
    Huang, Zi-Xiong
    Xu, Tao
    ASIAN JOURNAL OF ANDROLOGY, 2024, 26 (05): : 479 - 483
  • [6] A Prospective Study on the Efficacy of Cognitive Targeted Transrectal Ultrasound Prostate Biopsy in Diagnosing Clinically Significant Prostate Cancer
    Thangarasu, Mathisekaran
    Jayaprakash, Sanjay Prakash
    Selvaraj, Nivash
    Bafna, Sandeep
    Paul, Rajesh
    Mahesh, Chandranathan
    Jain, Nitesh
    Balakrishnan, Arunkumar
    Sivaraman, Ananthakrishnan
    RESEARCH AND REPORTS IN UROLOGY, 2021, 13 : 207 - 213
  • [7] Comparison of the complications of traditional 12 cores transrectal prostate biopsy with image fusion guided transperineal prostate biopsy
    Haifeng Huang
    Wei Wang
    Tingsheng Lin
    Qing Zhang
    Xiaozhi Zhao
    Huibo Lian
    Hongqian Guo
    BMC Urology, 16
  • [8] Comparison of the complications of traditional 12 cores transrectal prostate biopsy with image fusion guided transperineal prostate biopsy
    Huang, Haifeng
    Wang, Wei
    Lin, Tingsheng
    Zhang, Qing
    Zhao, Xiaozhi
    Lian, Huibo
    Guo, Hongqian
    BMC UROLOGY, 2016, 16 : 1 - 6
  • [9] Transrectal ultrasound biopsy of the prostate: does it still have a role in prostate cancer diagnosis?
    Moe, Andrew
    Hayne, Dickon
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 (06) : 3018 - 3024
  • [10] Role of targeted biopsy, perilesional biopsy, and random biopsy in prostate cancer diagnosis by mpMRI/transrectal ultrasonography fusion biopsy
    Novara, Giacomo
    Zattoni, Fabio
    Zecchini, Giovanni
    Aceti, Alberto
    Pellizzari, Anna
    Ferraioli, Giordana
    Carlesso, Maria
    La Bombarda, Giulia
    Morlacco, Alessandro
    Lacognata, Carmelo Salvino
    Lauro, Alberto
    Gardiman, Marina
    Betto, Giovanni
    Zanovello, Nicola
    Moro, Fabrizio Dal
    WORLD JOURNAL OF UROLOGY, 2023, 41 (11) : 3239 - 3247